FindTrial
Sign In

Treatment of Fatty Liver with Unani Drugs

Therapeutic Evaluation of Unani Pharmacopoeial Formulation in the Management of Non-Alcoholic Fatty Liver Disease (NAFLD)- A Single Blind Randomised Placebo Controlled Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/08/056748
Enrollment
60
Registered
2023-08-22
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Powder of Unani Pharmacopoeial formulation: Contents of Unani Pharmacopoeial formulation: Luk maghsool (Tachardia lacca) 10.5gm Rewand cheeni (Rheum emodi) 10.5gm Tukhm-e-karafs (Apium
each capsule is of 500 mg.

Sponsors

Department of Moalejat, Ajmal Khan Tibbiya College, Aligarh Muslim University, Aligarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient of either gender 2.Age between 20-60 years 3.Non alcoholic 4.BMI = 35 kg/M2 5.Diagnosed case of fatty liver by ultrasound (Upto Grade II) 6.Asymptomatic and symptomatic (anorexia, nausea, dyspepsia, and right hypochondrial discomfort) 7.Patient is able to participate in study and ready to follow the instructions and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Age 60 years. 2.BMI >35kg/M2. 3.Positive hepatitis marker. 4.Patients suffering from cardiopulmonary, renal disease, malignancy and uncontrolled type 2 diabetes mellitus. 5.Patients with severe deranged lipid profile and liver function test. 6.Patients receiving treatment with drugs such as oestrogens, corticosteroids, sodium valproate, tamoxifen and statins. 7.Pregnant and lactating women. 8.Non-compliant patients. 9.Patients failed to follow up.

Design outcomes

Primary

MeasureTime frame
Improvement in objective parameters USG findings of fatty liver 1.No improvement 2.Partial improvement 3.Complete improvement Timepoint: 2 months on baseline & after completion—

Secondary

MeasureTime frame
Improvement in subjective parameters 1.Anorexia 2.Nausea 3.Dyspepsia 4.Dull ache /Heaviness in right hypochondrium Timepoint: 2 months on Fortnightly follow ups—

Countries

India

Contacts

Public ContactDr Musab Siddique

Department of Moalejat, Ajmal Khan Tibbiya College, Aligarh Muslim University

drbdkhanamu@gmail.com9412333174

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026